Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

Weihuan Shao,Yiran Yao,Ludi Yang,Xiaoran Li,Tongxin Ge,Yue Zheng,Qiuyi Zhu,Shengfang Ge,Xiang Gu,Renbing Jia,Xin Song,Ai Zhuang

DOI: https://doi.org/10.1186/s40164-024-00504-8

2024-04-05

Experimental Hematology and Oncology

Abstract:Adoptive immunotherapy in the T cell landscape exhibits efficacy in cancer treatment. Over the past few decades, genetically modified T cells, particularly chimeric antigen receptor T cells, have enabled remarkable strides in the treatment of hematological malignancies. Besides, extensive exploration of multiple antigens for the treatment of solid tumors has led to clinical interest in the potential of T cells expressing the engineered T cell receptor (TCR). TCR-T cells possess the capacity to recognize intracellular antigen families and maintain the intrinsic properties of TCRs in terms of affinity to target epitopes and signal transduction. Recent research has provided critical insight into their capability and therapeutic targets for multiple refractory solid tumors, but also exposes some challenges for durable efficacy. In this review, we describe the screening and identification of available tumor antigens, and the acquisition and optimization of TCRs for TCR-T cell therapy. Furthermore, we summarize the complete flow from laboratory to clinical applications of TCR-T cells. Last, we emerge future prospects for improving therapeutic efficacy in cancer world with combination therapies or TCR-T derived products. In conclusion, this review depicts our current understanding of TCR-T cell therapy in solid neoplasms, and provides new perspectives for expanding its clinical applications and improving therapeutic efficacy.

oncology,hematology

What problem does this paper attempt to address?

The paper primarily explores the latest advancements and challenges in T-cell receptor (TCR) T-cell therapy for the treatment of solid tumors and attempts to optimize this therapy to enhance its clinical efficacy.

Specifically, the paper aims to address the following key issues:
1. **Screening and Identification of Tumor Antigens**: The paper introduces the selection criteria and identification methods for tumor-associated antigens (TAA) and tumor-specific antigens (TSA) that can be used in TCR-T cell therapy.
2. **Acquisition and Optimization of TCR**: It describes how to screen and identify target proteins through genomic technologies and comprehensively determine the tumor specificity of TCR sequences and structures.
3. **Enhancing the Efficacy of TCR-T Cell Therapy**: The paper discusses the limiting factors in current therapies and proposes methods to improve the effectiveness of TCR-T cell therapy in the future, including combining with other treatments or developing TCR-T derivatives.
4. **Complete Process from Laboratory to Clinical Application**: It summarizes the overall process of TCR-T cell therapy from laboratory research to clinical application.

Through these aspects of the review, the paper aims to provide new perspectives on the application of TCR-T cell therapy in the treatment of solid tumors and to promote its clinical application and efficacy improvement.